| Her-2在乳腺癌内分泌治疗中的地位评价 |
| |
| 引用本文： | 吴世凯,宋三泰. Her-2在乳腺癌内分泌治疗中的地位评价[J]. 肿瘤研究与临床, 2006, 18(5): 289-291 |
| |
| 作者姓名： | 吴世凯 宋三泰 |
| |
| 作者单位： | 100071,北京,军事医学科学院附属医院乳腺癌内科 |
| |
| 摘 要： | 对于激素受体阳性、Her-2基因异常的乳腺癌患者，如何选择内分泌药物一直是临床医生面临的问题。综合目前大量资料显示，Her-2过度表达与临床疗效间存在显著的负性相关性，三苯氧胺和第三代芳香化酶抑制剂对该组患者均疗效较差。化疗或化疗联合赫赛汀应是该组患者的优先选择，内分泌治疗联合赫赛汀可作为治疗策略的研究方向。
|
| 关 键 词： | Her-2基因 乳腺癌 内分泌治疗 |
| 文章编号： | 1006-9801（2006）05-0289-03 |
| 收稿时间： | 2006-04-22 |
| 修稿时间： | 2006-04-28 |
Evaluating the role of Her-2 in endocrine therapy for breast cancer |
| |
| WU Shi-kai,SONG San-tai. Evaluating the role of Her-2 in endocrine therapy for breast cancer[J]. Cancer Research and Clinic, 2006, 18(5): 289-291 |
| |
| Authors: | WU Shi-kai SONG San-tai |
| |
| Affiliation: | Department of Breast Cancer, Affiliated Hospital of the Military Medical Science, Beijing 100071, China |
| |
| Abstract: | How to select endocrine agents for patients with ER-positive/Her-2 -positive breast cancer has been a difficult question. Increasing evidences shows a consistent results that an association between Her-2 overexpression and poor response of endocrine treatment, tamoxifen and the third generation aromatase inhibitors has the similar poor efficacy. The treatment strategy for such patients should prefer chemotherapy alone or in combination with trastuzumab, and endocrine therapy combining with trastuzumab may be the development strategy, |
| |
| Keywords: | Endocrine agents Her-2 Breast cancer |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
| 点击此处可从《肿瘤研究与临床》浏览原始摘要信息 |
|
点击此处可从《肿瘤研究与临床》下载免费的PDF全文 |
